Harnessing Regulatory T (TReg) Cells to Transform Autoimmune Disease Treatment
Decades of research have revealed a critical insight: Immune system dysfunction in autoimmune diseases isn’t just about overactivity—it’s about imbalance. Sonoma Biotherapeutics is leading the way in restoring that balance through cell therapy, leveraging discoveries made by co-founder and CEO Jeff Bluestone, Ph.D., over the past 20+ years at UC San Francisco. His groundbreaking work on the IL-2 pathway and TReg cells now drives Sonoma’s mission to create durable, disease-modifying treatments.
By expanding and enhancing a patient’s own TReg cells, Sonoma is developing therapies that don’t just suppress symptoms but instead reset immune equilibrium. With a deep commitment to scientific innovation and collaboration, Sonoma is working to bring this new class of medicine to patients, overcoming the complexities of scaling cell therapies and ushering in a new chapter in autoimmune treatment.
Your innovation is our passion.
At Biocom California, our members are shaping the future of the life science industry and creating life-changing impact stories through their research and discoveries. From early stage biotech firms to established industry leaders, these stories showcase the passion, collaboration and ingenuity driving the future of healthcare and scientific innovation.
Many voices. One story.
Our members are visionaries, dedicated wholly to the pursuit of something unknown. Nurtured by the world’s largest clusters of life science communities, their ideas transform into a living ecosystem that connects people, creates community, drives progress and turns opportunity into life-changing discoveries. Along the way, our members are shaping the very stories that write history.
What’s Your Story?